Works by Pore, Nabendu


Results: 7
    1

    Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.

    Published in:
    Leukemia & Lymphoma, 2024, v. 65, n. 12, p. 1789, doi. 10.1080/10428194.2024.2373331
    By:
    • Dimopoulos, Meletios A.;
    • Migkou, Magdalini;
    • Bhutani, Manisha;
    • Ailawadhi, Sikander;
    • Kalff, Anna;
    • Walcott, Farzana L.;
    • Pore, Nabendu;
    • Brown, Miranda;
    • Wang, Fujun;
    • Cheng, Lily I.;
    • Kagiampakis, Ioannis;
    • Williams, Marna;
    • Kinneer, Krista;
    • Wu, Yuling;
    • Jiang, Yu;
    • Kubiak, Robert J.;
    • Zonder, Jeffrey A.;
    • Larsen, Jeremy;
    • Sirdesai, Shreerang;
    • Yee, Andrew J.
    Publication type:
    Article
    2
    3
    4
    5

    Epidermal Growth Factor Receptor Inhibition Modulates the Microenvironment by Vascular Normalization to Improve Chemotherapy and Radiotherapy Efficacy.

    Published in:
    PLoS ONE, 2009, v. 4, n. 8, p. 1, doi. 10.1371/journal.pone.0006539
    By:
    • Cerniglia, George J.;
    • Pore, Nabendu;
    • Tsai, Jeff H.;
    • Schultz, Susan;
    • Mick, Rosemarie;
    • Regine Choe;
    • Xiaoman Xing;
    • Durduran, Turgut;
    • Yodh, Arjun G.;
    • Evans, Sydney M.;
    • Koch, Cameron J.;
    • Hahn, Stephen M.;
    • Quon, Harry;
    • Sehgal, Chandra M.;
    • Lee, William M. F.;
    • Maity, Amit
    Publication type:
    Article
    6
    7